Trastuzumab adds to adjuvant chemotherapy for resected HER2-positive breast cancer

被引：3
|
作者：
Hudis, CA [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Breast Canc Med Serv, New York, NY 10021 USA
来源：
NATURE CLINICAL PRACTICE ONCOLOGY | 2006年 / 3卷 / 01期
关键词：
breast cancer; chemotherapy; HER2; survival; trastuzumab;
D O I：
10.1038/ncponc0401
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：12 / 13
页数：2
相关论文
共 50 条
  • [1] Adjuvant Trastuzumab in HER2-Positive Breast Cancer
    Slamon, Dennis
    Eiermann, Wolfgang
    Robert, Nicholas
    Pienkowski, Tadeusz
    Martin, Miguel
    Press, Michael
    Mackey, John
    Glaspy, John
    Chan, Arlene
    Pawlicki, Marek
    Tamas Pinter
    Valero, Vicente
    Liu, Mei-Ching
    Sauter, Guido
    von Minckwitz, Gunter
    Visco, Frances
    Bee, Valerie
    Buyse, Marc
    Bendahmane, Belguendouz
    Tabah-Fisch, Isabelle
    Lindsay, Mary-Ann
    Riva, Alessandro
    Crown, John
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (14) : 1273 - 1283
  • [2] Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer
    Mariani, Gabriella
    Fasolo, Angelica
    De Benedictis, Elena
    Gianni, Luca
    NATURE CLINICAL PRACTICE ONCOLOGY, 2009, 6 (02): : 93 - 104
  • [3] Trastuzumab improves locoregional control in HER2-positive breast cancer patients following adjuvant radiotherapy
    Cao, Lu
    Cai, Gang
    Xu, Fei
    Yang, Zhao-Zhi
    Yu, Xiao-Li
    Ma, Jin-Li
    Zhang, Qian
    Wu, Jiong
    Guo, Xiao-Mao
    Chen, Jia-Yi
    MEDICINE, 2016, 95 (32)
  • [4] Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer
    Haq, Bushra
    Geyer, Charles E.
    WOMENS HEALTH, 2009, 5 (02) : 135 - 147
  • [5] The Adjuvant Treatment of HER2-Positive Breast Cancer
    Jelovac, Danijela
    Wolff, Antonio C.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2012, 13 (02) : 230 - 239
  • [6] Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer
    McArthur, Heather L.
    Mahoney, Kathleen M.
    Morris, Patrick G.
    Patil, Sujata
    Jacks, Lindsay M.
    Howard, Jane
    Norton, Larry
    Hudis, Clifford A.
    CANCER, 2011, 117 (24) : 5461 - 5468
  • [7] An Economic Evaluation of Adjuvant Trastuzumab Therapy in HER2-Positive Early Breast Cancer
    Chen, Wen
    Jiang, Zefei
    Shao, Zhimin
    Sun, Qiang
    Shen, Kunwei
    VALUE IN HEALTH, 2009, 12 : S82 - S84
  • [8] Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer
    Costa, R. B.
    Kurra, G.
    Greenberg, L.
    Geyer, C. E.
    ANNALS OF ONCOLOGY, 2010, 21 (11) : 2153 - 2160
  • [9] Docetaxel, cyclophosphamide, and trastuzumab as neoadjuvant chemotherapy for HER2-positive primary breast cancer
    Nakatsukasa, Katsuhiko
    Koyama, Hiroshi
    Oouchi, Yoshimi
    Imanishi, Seiichi
    Mizuta, Naruhiko
    Sakaguchi, Kouichi
    Fujita, Yoshifumi
    Imai, Aya
    Okamoto, Akiko
    Hamaoka, Asako
    Soushi, Mari
    Fujiwara, Ikuya
    Kotani, Tatsuya
    Matsuda, Takayuki
    Fukuda, Kenichirou
    Morita, Midori
    Kawakami, Sadao
    Kadotani, Yayoi
    Konishi, Eiichi
    Yanagisawa, Akio
    Goto, Mariko
    Yamada, Kei
    Taguchi, Tetsuya
    BREAST CANCER, 2017, 24 (01) : 92 - 97
  • [10] Phosphorylated HER3 and FITC-labeled trastuzumab immunohistochemistry in patients with HER2-positive breast cancer treated with adjuvant trastuzumab
    Kanomata, Naoki
    Kurebayashi, Junichi
    Moriya, Takuya
    MEDICAL MOLECULAR MORPHOLOGY, 2019, 52 (02) : 106 - 113
12345